Information Provided By:
Fly News Breaks for December 17, 2019
HZNP, GBT, AIMT
Dec 17, 2019 | 05:33 EDT
Analysts at Piper Jaffray are buyers of Aimmune Therapeutics (AIMT), Global Blood Therapeutics (GBT) and Horizon Pharma (HZNP) into expected 2020 launches. Over the last five years, more launches have underperformed than outperformed, and the stock reactions have been largely proportionate to the level of under/over performance, the analysts tell investors in a research note. However, they point out that under the "somewhat rare circumstances" where performance has beaten expectations meaningfully, the stock reactions "can pay off handsomely." As such, Piper believes these three stocks can beat the "well entrenched biopharma default thesis to 'short the launch.'"
News For AIMT;GBT;HZNP From the Last 2 Days
HZNP
Aug 5, 2021 | 07:52 EDT
BMO Capital analyst Gary Nachman raised the firm's price target on Horizon Therapeutics to $132 from $118 and keeps an Outperform rating on the shares. The company's Q2 result were an "impressive" beat and raise, with the upside driven by Tepeza relaunch following Q1 supply disruption and faster than expected acceleration in demand, the analyst tells investors in a research note. Nachman adds that Horizon's pipeline "remains underappreciated" and is "progressing nicely", which will be highlighted on the company's R&D day.
GBT
Aug 4, 2021 | 12:12 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.  1... To see the rest of the story go to thefly.com. See Story Here
GBT
Aug 4, 2021 | 09:59 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Camping World (CWH) upgraded to Outperform from Neutral at Baird with analyst Craig Kennison saying in an "extremely tight market," Camping World made the most of the inventory shortage to drive record profitability in Q2. 2. BJ's Restaurants (BJRI) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Mullan saying the risk/reward "seems better now" with the stock down 39% from the March high. 3. Gaming and Leisure Properties (GLPI) upgraded to Buy from Neutral at UBS with analyst Robin Farley saying the shares should re-rate on the resilience of the company's tenants and strength of it leases. 4. Under Armour (UAA) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss seeing a favorable risk/reward setup following the stock's 75% underperformance relative to the retail sector over the past 18 months. 5. Global Blood Therapeutics (GBT) upgraded to Buy from Hold at Truist with analyst Joon Lee saying the company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GBT
Aug 4, 2021 | 08:24 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a price target of $50, up from $45. The company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock, the analyst tells investors in a research note. With about 7K total patients prescribed and two commercial catalysts expected in the first half of FY22, shares of Global Blood Therapeutics will rebound after a year of underperformance, Lee adds.
GBT
Aug 4, 2021 | 05:13 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a $50 price target.